UK markets close in 4 hours 39 minutes
  • FTSE 100

    7,401.27
    -92.86 (-1.24%)
     
  • FTSE 250

    21,767.89
    -495.35 (-2.22%)
     
  • AIM

    1,097.79
    -34.29 (-3.03%)
     
  • GBP/EUR

    1.1933
    -0.0014 (-0.11%)
     
  • GBP/USD

    1.3494
    -0.0052 (-0.38%)
     
  • BTC-GBP

    25,125.93
    -1,459.32 (-5.49%)
     
  • CMC Crypto 200

    772.52
    +529.84 (+218.33%)
     
  • S&P 500

    4,397.94
    -84.79 (-1.89%)
     
  • DOW

    34,265.37
    -450.03 (-1.30%)
     
  • CRUDE OIL

    84.88
    -0.26 (-0.31%)
     
  • GOLD FUTURES

    1,839.20
    +7.40 (+0.40%)
     
  • NIKKEI 225

    27,588.37
    +66.11 (+0.24%)
     
  • HANG SENG

    24,656.46
    -309.09 (-1.24%)
     
  • DAX

    15,314.12
    -289.76 (-1.86%)
     
  • CAC 40

    6,937.06
    -131.53 (-1.86%)
     

3 COVID Pill Stocks That Might Be Game-Changers

·4-min read
3 COVID Pill Stocks That Might Be Game-Changers
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • PFE
  • VXRT

Despite the tremendous success of vaccines against the coronavirus, there's always more work to be done when it comes to reducing the risks associated with infection. If coronavirus vaccine development was the story of 2020, antiviral pill development might well be the story of 2021 and 2022. Pfizer (NYSE: PFE) is currently working on an antiviral pill for COVID-19 to add to its profitable coronavirus portfolio, where its highly successful vaccine is front and center.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting